Completed PHASE3 INTERVENTIONAL 3-arm NCT02326272

A Study to Evaluate the Efficacy and Safety of Two Dose Levels of Certolizumab Pegol (CZP) in Subjects With Plaque Psoriasis (PSO) (CIMPASI-2)

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Group, Study Followed by a Dose-Blind Period and Open-Label Follow-Up to Evaluate the Efficacy and Safety of Certolizumab Pegol in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Sponsor: UCB Biopharma S.P.R.L.

Conditions Plaque Psoriasis Psoriasis

Interventions Certolizumab Pegol Placebo

Updated 13 times since 2017 Last updated: Sep 11, 2019 Started: Dec 15, 2014 Primary completion: Jan 5, 2016 Completion: Sep 12, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Plaque Psoriasis and Psoriasis and is currently completed. UCB Biopharma S.P.R.L. leads this study, which shows 13 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

13 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Nov 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 8 earlier versions

Nov 2018 — Nov 2019 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Sep 2018 — Nov 2018 [monthly]

Active Not Recruiting PHASE3
Jun 2018 — Sep 2018 [monthly]

Active Not Recruiting PHASE3
Feb 2018 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Oct 2017 — Feb 2018 [monthly]

Active Not Recruiting PHASE3
Jun 2017 — Oct 2017 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

UCB Biopharma S.P.R.L.

Data source: UCB Pharma

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bakersfield, United States , Barrie, Canada , Cleveland, United States , East Windsor, United States , Graz, Austria , Greer, United States , Kielce, Poland , Krakow, Poland , London, Canada , New York, United States and 13 more locations